兴齐眼药(300573) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 419,392,763.76, representing a 3.89% increase year-over-year, while the year-to-date revenue reached CNY 1,104,863,512.43, up 10.02% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was CNY 94,576,870.38, a 15.05% increase year-over-year, but the year-to-date net profit decreased by 10.11% to CNY 182,331,511.64[3]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.76, reflecting a 15.15% increase from the same period last year[3]. - The total comprehensive income for the third quarter was CNY 182,331,511.64, a decrease from CNY 202,837,956.65 in the previous period, representing a decline of approximately 10%[20]. - Basic and diluted earnings per share for the period were both CNY 1.47, down from CNY 1.64 in the previous period, indicating a decrease of about 10.37%[20]. Research and Development - Research and development expenses increased by 34.39% year-over-year to CNY 121,550,678.54, indicating a significant investment in innovation[8]. - Research and development expenses increased to ¥121,550,678.54 from ¥90,447,355.09, marking a significant rise of approximately 34.4%[19]. - The company has made progress in drug development, obtaining a drug registration certificate for Diquafosol Sodium Eye Drops[14]. - The first subject has been enrolled in the Phase I clinical trial for Voriconazole Eye Drops, marking a significant milestone in its development[14]. - The company has terminated the clinical trial for Tacrolimus Suspension Eye Drops, indicating a strategic shift in its product pipeline[14]. Assets and Liabilities - Total assets as of the end of Q3 2023 were CNY 1,918,370,381.12, a 7.60% increase from the end of the previous year[3]. - As of September 30, 2023, the total assets of the company reached ¥1,918,370,381.12, an increase from ¥1,782,942,843.86 at the beginning of the year, representing a growth of approximately 7.6%[16]. - The company reported a decrease in total liabilities from ¥152,445,128.89 to ¥248,907,751.47, reflecting a significant increase in financial obligations[16]. Cash Flow - The company reported a net cash flow from operating activities of CNY 225,936,626.98 year-to-date, which is a decrease of 12.59% compared to the same period last year[3]. - Cash inflow from operating activities amounted to CNY 1,059,437,010.02, an increase from CNY 1,001,760,708.35 in the previous period, reflecting a growth of approximately 5.7%[21]. - Net cash flow from operating activities was CNY 225,936,626.98, compared to CNY 258,481,192.79 in the previous period, showing a decrease of about 12.6%[22]. - Cash outflow from investing activities was CNY 188,572,666.89, down from CNY 242,112,738.05 in the previous period, indicating a reduction of approximately 22.1%[22]. - Net cash flow from financing activities was negative CNY 120,914,243.87, an improvement from negative CNY 186,731,168.79 in the previous period, reflecting a decrease in cash outflow of about 35.2%[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,921, with the largest shareholder, Liu Jidong, holding 28.59% of shares, equating to 35,441,700 shares[10]. - Liu Jidong's restricted shares increased from 18,986,625 to 26,581,275, with 7,594,650 shares added during the reporting period[13]. - The top ten shareholders hold a combined total of 50.88% of the shares, indicating a concentrated ownership structure[12]. - The total number of restricted shares at the end of the reporting period is 28,735,689, reflecting the company's management of executive compensation[13]. - The company has not disclosed any known relationships or concerted actions among the top shareholders, maintaining transparency in shareholder dynamics[12]. Business Development - The company established new branches in Nanjing and Guangzhou during the reporting period to support business development[15]. - The company continues to explore market expansion opportunities, as evidenced by its ongoing clinical trials and product registrations[14]. Other Financial Metrics - The company's short-term borrowings increased to CNY 50,000,000.00, marking a 100% increase during the reporting period[7]. - The company experienced a significant increase in accounts receivable, which rose by 58.66% to CNY 196,645,598.04, primarily due to delayed payments[7]. - The company reported a decrease in government subsidies received, which fell by 95.86% to CNY 85,561.90 compared to the same period last year[8]. - The company's cash and cash equivalents decreased to ¥425,355,427.88 from ¥515,449,608.39, a decline of about 17.5%[15]. - The inventory level rose to ¥124,373,298.32 from ¥122,270,757.79, indicating a slight increase of about 1.7%[16]. - The company paid CNY 177,926,075.99 in dividends and interest, compared to CNY 80,712,479.18 in the previous period, which is an increase of approximately 120.5%[22]. Audit Status - The report for the third quarter was not audited[24].